Demand for anti-superbug remedies boosts sales outlook at Teva supplier Venus Remedies; Recipharm grabs manufacturing deal from Astimex Pharma;

> Peru's tougher GMP requirements on drugmakers have stymied the approval of new drugs in the country. Article

> Venus Remedies, an India-based supplier of meds for Teva Pharmaceutical Industries ($TEVA), expects 15% growth in sales over the next two years in part because of demand for anti-bacterial drugs against superbugs. Report

> Recipharm sealed a development manufacturing deal with Astimex Pharma. Item

> Under a deal announced Monday, Ark Therapeutics Group will manufacture and provide Lymfactin to Laurantis Pharma. Report

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.